Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

D. Bradley, Jeffrey; Hu, Chen; Komaki, Ritsuko; A. Masters, Gregory; R. Blumenschein, George; E. Schild, Steven; A. Bogart, Jeffrey; Forster, Kenneth; M. Magliocco, Anthony; S. Kavadi, Vivek; Narayan, Samir; Iyengar, Puneeth; G. Robinson, Clifford; B. Wynn, Raymond; D. Koprowski, Christopher; R. Olson, Michael; Meng, Joanne; Paulus, Rebecca; J. Curran, Walter; Choy, Hak

doi:10.1200/jco.19.01162

Public

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

Published in Journal of Clinical Oncology • Dec 16, 2019

Authors:

Jeffrey D. Bradley

Chen Hu

Ritsuko Komaki

Abstract

PURPOSE RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non–small-cell lung cancer (NSCLC). METHODS The study used a 2 × 2 factorial design with radiation dose as 1 factor and cetu...

Subject

Medicine

Cetuximab

Esophagitis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!